Nexentis Technologies

NXTS

Market cap $3.33M

MitoCareX Bio completes comprehensive SLC transport protein analysis to support discovery of small molecules for hard-to-treat cancers and inflammatory metabolic diseases and enters an AI-driven small-molecule discovery initiative with Boltz

Neve Yarak, Israel, June 29, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced the signing of an Addendum to the Loan and Partnership Agreement, together with Solterra Renewable Energy Ltd. (“Solterra”) and the other lenders, for its Melz solar PV project in Germany.

MITOLINE ® -Enabled 3D Structural Modeling and Boltz AI Capabilities to Be Combined by MitoCareX in a Synergistic Virtual Screening Campaign for selected Transporter Targets

Ness Ziona, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), today reported that it has completed a broad structural analysis of human SLC (Solute Carrier) transport proteins as part of its ongoing efforts to expand and refine its small-molecule discovery capabilities.

Ness Ziona, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has successfully achieved its first drug discovery milestone since its acquisition by Nexentis: the generation of an optimized hit molecule with substantially improved pharmaceutical properties compared to the program's initial hit compound.

MITOLINE ® -Powered Platform Delivers Optimized Hit Molecule, Strengthening the Foundation for Future Pre-Clinical and Commercial Development

Neve Yarak, Israel, May 05, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS), (“Nexentis” or the “Company”), a drug discovery company that is also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. (“MitoCareX”), has received official trademark registration from the United States Patent and Trademark Office (USPTO) for its proprietary algorithm platform, MITOLINE™.

Vancouver, British Columbia, February 19, 2026 – TheNewswire –  This press release is being disseminated as required b y National Instrument 62-103 The Early Warning System and Related Take-Over Bid and Insider Reporting Issues (“NI 62-103”). The requirement to provide this disclosure was triggered by an increase in Plantify Foods, Inc.'s (“ Plantify ”) issued and outstanding share capital on February 18, 2026, as a result of the closing of a Private Placement.

Neve Yarak, Israel, Feb. 02, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the  RTB (Ready to Build) business model, today highlighted a newly published peer-reviewed study co-authored by Prof. Ciro Leonardo Pierri, co-founder of MitoCareX Bio Ltd. (“MitoCareX Bio”), a specialty biotechnology company developing small‑molecule drugs that target human mitochondrial carriers, its wholly- owned subsidiary. The article, appearing in the Journal of Translational Medicine, investigates SLC25A mitochondrial carriers as potential biomarkers and therapeutic targets for dysfunctions induced by spaceflight conditions, including microgravity and cosmic radiation.

MITOLINE™ Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for Inflammatory Metabolic Diseases – A Market Projected to Exceed $120 billion by 2030